SAN FRANCISCO, March 9 (Reuters) - Nabi Biopharmaceuticals (NABI.O: Quote, Profile, Research), a maker of drugs to treat bacterial infections, kidney and liver disease, said on Thursday it had appointed Adam Logal as its interim chief financial officer.
